Form 8-K

8-K — LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Accession: 0001493152-26-017833

Filed: 2026-04-17

Period: 2026-04-15

CIK: 0001335105

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-10.1 (ex10-1.htm)

EX-10.2 (ex10-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001335105

2026-04-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of Report (Date of earliest event reported): April 15, 2026

LIXTE

BIOTECHNOLOGY HOLDINGS, INC.

(Exact

name of registrant as specified in its charter)

delaware

001-39717

20-2903526

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

Number)

433

Plaza Real, Suite 275

Boca

Raton, Florida 33432

(Address

of principal executive offices)

(631)

830-7092

(Registrant’s

telephone number, including area code)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (See General Instruction A.2. below):

☐

Written communications

pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of Each Class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, par value

$0.0001 per share

LIXT

The NASDAQ Stock Market,

LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

April 15, 2026, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Lixte

Biotechnology Holdings, Inc., (the “Company”), approved the cancellation of stock options (the “Cancelled

Options”) previously granted to the officers and directors of the Company listed below, and the grant of restricted share

units (“RSUs”) in replacement thereof. The RSUs were awarded under the Company’s 2020 Stock Incentive Plan (the

“Plan”). Each RSU represents the right to receive one share of the Company’s common stock upon vesting. The RSUs

vested on the date of issuance and are subject to the terms and conditions of the Plan and the applicable award agreement.

Name

Title

Options Cancelled

RSU Awarded

Geordan Pursglove

Chief Executive Officer

350,000

Peter Stazzone

Chief Financial Officer

50,000

Michael Holloway

Director

25,000

Guy Primus

Director

25,000

Lourdes Felix

Director

25,000

Jason Sawyer

Director

25,000

The

Committee determined that the cancellation of the Cancelled Options and grant of the RSUs was in the best interests of the Company and

its stockholders, as it provides a more effective retention and incentive mechanism for the officers and directors listed above.

The

foregoing description of the RSU award and Option cancellation does not purport to be complete and are qualified in their entirety by

reference to the form of RSU Award Agreement and Stock Option Cancellation Agreement, which are filed as Exhibit 10.1 and 10.2 respectively

to this Current Report on Form 8-K and incorporated herein by reference.

Item

9.01 Financial Statements and Exhibits

(d)

Exhibits. The following exhibits are filed herewith.

Exhibit

Number

Description

10.1

Form of Restricted Share Unit Agreement.

10.2

Form of Stock Option Cancellation Agreement.

104

Cover Page Interactive

Data File (embedded within the inline XBRL Document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date: April 17, 2026

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Registrant)

By:

/s/

Geordan Pursglove

Chairman of the Board

and Chief Executive Officer

EX-10.1

Filename: ex10-1.htm · Sequence: 2

Exhibit 10.1

RESTRICTED

SHARE UNIT AWARD AGREEMENT

This

Restricted Share Unit Award Agreement (this “Agreement”) is made and entered into as of __, 2026 (the “Grant

Date”) by and between Lixte Biotechnology Holdings, Inc., a Delaware Corporation (the “Company”), and _____

(the “Grantee”).

WHEREAS,

the Company has adopted the Lixte Biotechnology, Inc. 2020 Stock Incentive Plan, as amended (the “Plan”) pursuant

to which awards of Restricted Share Units may be granted; and

WHEREAS,

the Committee has determined that it is in the best interests of the Company and its shareholders to grant the award of Restricted Share

Units provided for herein.

NOW,

THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

Grant of Restricted Share Units. Pursuant to

Section 7 of the Plan, the Company hereby issues to the Grantee on the Grant Date _____ Restricted Share Units (the “Restricted

Share Units”), on the terms and conditions and subject to the restrictions set forth in this Agreement and the Plan. Capitalized

terms that are used but not defined herein have the meaning ascribed to them in the Plan.

Consideration. The grant of the Restricted Share

Units is made in consideration of the services rendered by the Grantee to the Company.

Vesting. Except as otherwise provided herein,

provided that the Grantee remains in Continuous Service through the applicable vesting date, and further provided that any additional

conditions and performance goals set forth below have been satisfied, the Restricted Share Units will vest immediately upon the grant

Date.

Settlement. For each Restricted Share Unit that

becomes vested in accordance with Sections 3, the Company shall issue and deliver to Grantee, on or within sixty (60) days after becoming

vested (or in the event of vesting upon a Change in Control immediately prior to the date of the Change in Control), one share of common

stock, par value $0.0001 per share, of the Company (each a “Common Share”). The Company may issue share certificates

or evidence of the Grantee’s interest by using a book entry account with the Company’s transfer agent.

No Rights as Shareholder. The Grantee shall not

be entitled to any of the rights of a stockholder with respect to any Common Share that may be acquired following vesting of a Restricted

Share Unit unless and until such Common Share is issued and delivered to the Grantee. Without limitation of the foregoing, the Grantee

shall not have the right to vote a Common Share to which a Restricted Share Unit relates and shall not be entitled to receive any dividends

attributable to such Common Share for any period prior to the issuance and delivery of such Common Share to Grantee (but Grantee shall

have dividend equivalent rights as provided in Section 6 below).

Dividend Equivalent Units. If and to the extent

that the Company pays a cash dividend with respect to Common Shares, the Grantee shall be credited with an additional number of Restricted

Share Units (“Dividend Equivalent Units”), including a fractional Dividend Equivalent Unit if applicable, equal to

(i) the amount of such dividends as would have been paid with respect to the Grantee’s outstanding Restricted Share Units on the

record date of such dividend (the “record date”) had each such outstanding Restricted Share Unit been an outstanding

Common Share on such record date, divided by (ii) the closing price of an Common Share on such record date. Dividend Equivalent Units

shall be subject to the same vesting terms and conditions as the Restricted Share Units to which they relate.

No Right of Assignment. Neither this Agreement

nor the Restricted Share Units may be sold, assigned, pledged or otherwise transferred or encumbered without the prior written consent

of the Committee.

No Right to Continued Service. Neither the Plan

nor this Agreement shall confer upon the Grantee any employment rights or any right to be retained in any position, as an Employee, Consultant

or Director of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company

to terminate the Grantee’s Continuous Service at any time, with or without Cause.

Adjustments. If any change is made to outstanding

Common Shares or the capital structure of the Company, if required, the Restricted Share Units shall be adjusted or terminated in any

manner as contemplated by Section 10 of the Plan.

10.

Tax Liability and Withholding.

10.1.

The Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the

Grantee pursuant to the Plan, the amount of any required withholding taxes in respect of the Restricted Share Units and Common Shares

issued with respect thereto and to take all such other action as the Committee deems necessary to satisfy all obligations for the payment

of such withholding taxes. The Committee may permit the Grantee to satisfy any U.S. federal, state or local tax withholding obligation

by any of the following means, or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold

Common Shares from the Common Shares otherwise issuable or deliverable to the Grantee as a result of the vesting of the Restricted Share

Units; provided, however, that no Common Shares shall be withheld with a value exceeding the minimum amount of tax required to

be withheld by law; or (c) delivering to the Company previously owned and unencumbered Common Shares.

10.2.

Notwithstanding any action the Company takes with respect to any or all income tax, payroll tax, or other tax-related withholding (“Tax-Related

Items”), the ultimate liability for all Tax-Related Items is and remains the Grantee’s responsibility and the Company

(a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant or vesting

of the Restricted Share Units or the subsequent sale of any Common Shares; and (b) does not commit to structure the Restricted Share

Units to reduce or eliminate the Grantee’s liability for Tax-Related Items.

10.3.

To the extent that this Agreement and the Award of Restricted Share Units hereunder are or become subject to the provisions of Section

409A of the Code, the Company and the Grantee agree that this Agreement may be amended or modified by the Company, in its sole discretion

and without the Grantee’s consent, as appropriate to maintain compliance with the provisions of Section 409A of the Code.

11.

No Section 83(b) Election. The Grantee may not

make an election under Code Section 83(b) with respect to the Restricted Share Units.

12.

Compliance with Law. The issuance and transfer

of Common Shares shall be subject to compliance by the Company and the Grantee with all applicable requirements of U.S. federal and state

securities laws and with all applicable requirements of any stock exchange on which the Company’s Common Shares may be listed.

No Common Shares shall be issued or transferred unless and until any then applicable requirements of state and federal laws and regulatory

agencies have been fully complied with to the satisfaction of the Company and its counsel. The Grantee understands that the Company is

under no obligation to register the Common Shares with the Securities and Exchange Commission, any state securities commission or any

stock exchange to effect such compliance.

13.

Investment Purpose. Any and all Common Shares

acquired by the Grantee under this Agreement will be acquired for investment for the Grantee’s own account and not with a view

to, for resale in connection with, or with an intent of participating directly or indirectly in, any distribution of such Common Shares

within the meaning of the Securities Act of 1933, as amended.

14.

Lock-Up Agreement. In the event that any Common

Shares become deliverable to Grantee with respect to Restricted Share Units at a time during which any directors or officers of the Company

have agreed with one or more underwriters not to sell securities of the Company, the Grantee shall enter into an agreement, in form and

substance satisfactory to the Company, pursuant to which the Grantee shall agree to restrictions on transferability of the Common Shares

comparable to the restrictions agreed upon by such directors or officers of the Company.

15.

Legends. A legend may be placed on any certificate(s)

or other document(s) delivered to the Grantee indicating restrictions on transferability of the Common Shares issued pursuant to this

Agreement or any other restrictions that the Committee may deem advisable under the rules, regulations and other requirements of the

Securities and Exchange Commission, any applicable federal or state securities laws or any stock exchange on which the Common Shares

are then listed or quoted.

16.

Notices. Any notice required to be delivered

to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company at the Company’s registered

office. Any notice required to be delivered to the Grantee under this Agreement shall be in writing and addressed to the Grantee at the

Grantee’s address as shown in the records of the Company. Either party may designate another address in writing (or by such other

method approved by the Company) from time to time.

17.

Governing Law. This Agreement will be construed

and interpreted in accordance with the laws of the State of Delaware without regard to conflict of law principles (whether of the State

of Delaware or any other jurisdiction).

18.

Interpretation. Any dispute regarding the interpretation

of this Agreement shall be submitted by the Grantee or the Company to the Committee for review. The resolution of such dispute by the

Committee shall be final and binding on the Grantee and the Company.

19.

Restricted Share Units Subject to Plan. This

Agreement is subject to the Plan as approved by the Company’s shareholders. The terms and provisions of the Plan as it may be amended

from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein

and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.

20.

Successors and Assigns. The Company may assign

any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of

the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Grantee and the Grantee’s

beneficiaries, executors, administrators and the person(s) to whom the Restricted Share Units may be transferred by will or the laws

of descent or distribution.

21.

Severability. The invalidity or unenforceability

of any provision of the Plan or this Agreement shall not affect the validity or enforceability of any other provision of the Plan or

this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable to the extent permitted by law.

22.

Discretionary Nature of Plan. The Plan is discretionary

and may be amended, cancelled or terminated by the Company at any time, in its discretion. The grant of the Restricted Share Units in

this Agreement does not create any contractual right or other right to receive any Restricted Share Units or other Awards in the future.

Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not

constitute a change or impairment of the terms and conditions of the Grantee’s employment or service with the Company.

23.

Amendment. The Committee has the right to amend,

alter, suspend, discontinue or cancel the Restricted Share Units, prospectively or retroactively; provided, that, no such amendment

shall adversely affect the Grantee’s material rights under this Agreement without the Grantee’s consent.

24.

No Impact on Other Benefits. The value of the

Grantee’s Restricted Share Units is not part of his normal or expected compensation for purposes of calculating any severance,

retirement, welfare, insurance or similar employee benefit.

25.

Data Privacy Consent. In order to administer

the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain

agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including

but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information

that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”).

By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies

all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes

the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information

to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change,

the Relevant Information. Relevant Information will only be used in accordance with applicable law.

26.

Compensation Recovery Policy. By accepting the

Award, the Grantee acknowledges that the Grantee is fully bound by, and subject to all of the terms and conditions of, the Company’s

compensation recovery or “clawback” policy (the “Recovery Policy”), and the Grantee agrees to abide by

the terms of such Recovery Policy. To the extent that the Board or a committee thereof determines that all or a portion of the Award

or the Common Shares issued pursuant to the Award must be cancelled, forfeited, repaid, or otherwise recovered by the Company, the Grantee

shall promptly take whatever action is necessary to effectuate such cancellation, forfeiture, repayment, or recovery. No recovery pursuant

to the Recovery Policy of all or a portion of the Award or Common Shares issued thereunder will be an event giving rise to a right to

terminate for “good reason” under any agreement with the Company. In the event of any conflict between the terms of the Recovery

Policy and the terms of the Plan or this Agreement, the terms of the Recovery Policy shall govern.

27.

Counterparts. This Agreement may be executed

in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. Counterpart

signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by

any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect

as physical delivery of the paper document bearing an original signature.

28.

Acceptance. The Grantee hereby acknowledges receipt

of a copy of the Plan and this Agreement. The Grantee has read and understands the terms and provisions thereof, and accepts the Restricted

Share Units subject to all of the terms and conditions of the Plan and this Agreement. The Grantee acknowledges that there may be adverse

tax consequences upon the grant or vesting of the Restricted Share Units or disposition of the Common Shares issued in respect thereof

and that the Grantee has been advised to consult a tax advisor prior to such grant, vesting or disposition.

[SIGNATURE

PAGE FOLLOWS]

WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

COMPANY:

lixte

biotechnology holdings, inc.

By:

Name:

Geordan

Pursglove

Title:

Chief

Executive Officer

Address:

433

Plaza Real, Suite 275

Boca

Raton, Florida 33432

GRANTEE:

(Signature)

(Name)

EX-10.2

Filename: ex10-2.htm · Sequence: 3

Exhibit 10.2

STOCK

OPTION CANCELLATION AGREEMENT

THIS

STOCK OPTION CANCELLATION AGREEMENT (this “Agreement”) is made and entered into as of __, 2026, by and

between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and __ (“Optionholder”).

RECITALS

WHEREAS,

the Company previously granted to Optionholder the following stock option to purchase shares (the “Shares”)

of the Company’s Common Stock (the “Option”):

Date of Grant

Number

of Shares

Exercise

Price

[*]

$ [*]

WHEREAS,

as of the date of this Agreement, the entire Option remains unexercised.

WHEREAS,

the Company’s Board of Directors has determined that it is in the best interests of the Company and its stockholders to cancel

the Option in exchange for issuing Restricted Stock Units (“RSU’s”) in an amount equal to the Option

(the “Consideration”).

WHEREAS,

other than the Consideration, the Optionholder has not received, and will not receive any additional consideration in exchange for

the cancellation of the Option.

WHEREAS,

Optionholder has decided to voluntarily consent to this Agreement and the cancellation of the Option subject to the terms described

herein.

AGREEMENT

consideration of the mutual promises and covenants herein, the parties hereto, each intending to be legally bound, agree as follows:

Cancellation of Option. The Option is hereby canceled in exchange for the Company’s issuance of the RSU’s to Optionholder

pursuant to a Restricted Share Unit Agreement being executed contemporaneously herewith the receipt of which payment is hereby acknowledged.

Optionholder hereby irrevocably relinquishes any right or interest that Optionholder may have had, may have or may acquire in the future

with respect to the Option and to the Shares.

Return of Outstanding Option Documents. Immediately upon execution of this Agreement, Optionholder shall deliver to the Company all

copies of the stock option grant notice and stock option agreement previously delivered to Optionholder by the Company in connection

with the grant of the Option.

Further Assurances. Optionholder agrees to execute and/or cause to be delivered to the Company such instruments and other documents,

and shall take such other actions, as the Company may reasonably request for the purpose of carrying out or evidencing the cancellation

of the Option.

Legal Advice. Optionholder acknowledges and represents that Optionholder has had the opportunity to consult with a legal advisor

in connection with this Agreement and that Optionholder is not relying upon the Company for any legal advice.

Governing Law. This Agreement shall be governed in all respects by the laws of the State of Delaware, without regard to that State’s

conflicts of laws principles.

Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together

will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by

electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial

appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.

[SIGNATURE

PAGE FOLLOWS]

WITNESS WHEREOF, this Stock Option Cancellation Agreement has been executed by the parties hereto as of the date first above written.

COMPANY:

LIXTE

BIOTECHNOLOGY HOLDINGS, INC.

By:

Name:

Geordan

Pursglove

Title:

Chief

Executive Officer

OPTIONHOLDER:

By:

(signature)

Name:

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 15, 2026

Entity File Number

001-39717

Entity Registrant Name

LIXTE

BIOTECHNOLOGY HOLDINGS, INC.

Entity Central Index Key

0001335105

Entity Tax Identification Number

20-2903526

Entity Incorporation, State or Country Code

Entity Address, Address Line One

433

Plaza Real

Entity Address, Address Line Two

Suite 275

Entity Address, City or Town

Boca

Raton

Entity Address, State or Province

Entity Address, Postal Zip Code

33432

City Area Code

(631)

Local Phone Number

830-7092

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value

$0.0001 per share

Trading Symbol

LIXT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration